Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERC-301 in Severe Depression with Suicidal Ideation
NCT01941043Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- Nov 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rislenemdaz in major depressive disorder (MDD) and suicidal ideation (3 arms), sponsored by Avalo Therapeutics. Primary endpoint: Hamilton Depression Rating Scale-17 at 7 days. Started Nov 2013; status: completed.
02
Drugs
rislenemdaz
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on NCT01941043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941043.